Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hy... (and renal dysfunction. Adverse events...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia

Date:9/20/2007

and renal dysfunction.

Adverse events were mild or moderate in severity, and there were no differences in the rates of clinically meaningful serious adverse events across the study groups. However, discontinuations due to AEs were highest among patients given conivaptan 80 mg/day and were largely attributed to local infusion-site reactions.

Note: These study results were presented at the 2004 annual meeting of the Heart Failure Society of America in Toronto.

About Hyponatremia

Hyponatremia often results from elevated levels of the hormone arginine vasopressin (AVP), which regulates water and salt balance in the body. It is the most common electrolyte disorder in clinical medicine and one of the most difficult to treat.

Syndrome of inappropriate antidiuretic hormone (SIADH), advanced kidney failure, hypothyroidism, cancer and chronic high blood pressure are common causes of hyponatremia. Dilutional hyponatremia, which includes euvolemic and hypervolemic hyponatremia, is the most common form of the condition, and occurs when retained water dilutes serum sodium content. Patients with hyponatremia are classified as hypervolemic if swelling of body tissues (edema) is present or euvolemic if there is an increase in total body water content without edema.(1,2)

About VAPRISOL

Discovered and developed by Astellas Pharma Inc. headquartered in Tokyo, Japan, VAPRISOL is a novel drug that blocks the activity of AVP, resulting in increased urine output without loss of valuable electrolytes such as sodium and potassium. This effect, known as "aquaresis," helps to increase serum sodium levels in patients with hyponatremia, a condition of low serum sodium concentration, due to increased body water (dilutional hyponatremia). VAPRISOL is the first AVP receptor antagonist with a demonstrated safety profile and that effectively promotes aquaresis which helps to restore salt and water balance in patients with euvolemic and hypervolemic hyponatrem
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:

(Date:5/22/2013)... , May 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com ... China Pharmaceutical Guidebook Series (4) 2013 Edition Material ... for Imported Drug Registration: A Guidebook of Registration ... Medicines " to its online database. ... Chinese medicines are always regarded by occidental as ...

(Date:5/22/2013)... and VANCOUVER, British Columbia , May 22, ... a leader in the development of novel therapeutics to target ... trials of its investigational compounds, custirsen and OGX-427, will be ... Annual Meeting of the American Society of Clinical Oncology ... 31 – June 4. Despite the availability ...

(Date:5/21/2013)... BEIJING, May 21, 2013 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China and the parent ... results for the first quarter ended March 31, 2013 ... , Total net revenue, which consists of net revenues ...

[0] China Pharmaceutical Market Guidebook Series (4) 2013 Report [0] OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting [0] Concord Medical Reports First Quarter 2013 Financial Results

... of Inflammatory ... ... MOUNTAIN VIEW, Calif., May 13 ChemoCentryx, Inc., today,announced the initiation ... molecule compound designed to specifically,target the CCR1 chemokine receptor which is ...

... Business, DUBLIN, Ohio, May 12 Cardinal ... improve the safety and,productivity of health care, today ... privately held Enturia, Inc., the manufacturer of,infection prevention ... ChloraPrep(R) brand products are used widely in U.S. ...

Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2 ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3 ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4 ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5 Cardinal Health Completes Enturia Acquisition 2

ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 Cardinal Health Completes Enturia Acquisition

(Date:5/21/2013)... 2013 The University of Colorado’s Anschutz ... HEALTHY DINING to help Coloradans make healthier choices when ... program is called HEALTHY DINING IN COLORADO. More ... participating in Colorado. Restaurants will offer a selection of ... lean protein, vegetables, fruits, whole grains and unsaturated fats. ...

(Date:5/21/2013)... May 22, 2013 Swimsuit season is almost ... Whisperer ® products has begun with a 35% discount. , ... estrogen. Many women get the dreaded cellulite even if they ... the skin where they have been stored as toxic lymph ... no easy fixes, a specific program that works to dissolve ...

(Date:5/21/2013)... Dallas, Texas (PRWEB) May 22, 2013 ... globally increasing meat production industry value chain. Most of ... the form of injectable, pellets, liquids, and powders. There ... in different quantities and concentrations depending upon the type ... acids, minerals, and vitamins that provide essential nutrition to ...

(Date:5/21/2013)... George Washington (GW) University School of Public ... launch of the Avance Center for the ... SPHHS, the Maryland Multicultural Youth Centers, the ... university-community partnership aims to address public health ... research, mutual capacity building and prevention efforts. ...

(Date:5/21/2013)... Medical Ministry International announced today that it has ... GreatNonprofits , the leading provider of user reviews about nonprofit ... 2013 Nonprofit,” says Samuel Smith, MMI CEO. This does ... and Staff serving in 22 countries around the world. This ... have seen our work first hand and wanted to tell ...

Breaking Medicine News(10 mins):Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 2 Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 3 Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2 Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2 Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3 Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4 Health News:GW launches center to address health disparities in the Latino immigrant community 2 Health News:GW launches center to address health disparities in the Latino immigrant community 3 Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2

[0] Colorado Takes a Huge Step toward Transforming the Family Dining Experience [0] Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale"[0] Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com [0] GW launches center to address health disparities in the Latino immigrant community [0] Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org

... U.S. organ transplant system often fails to detect or fix ... according to the Los Angeles Times on Sunday. ... are usually kept a secret leaving patients and their families ... ,This nonprofit agency has been given the contract ...

... at the Indian Institute of Technology (IIT), Chennai, have ... them into cells, a// major step towards drug efficacy. ... that comprises a core of one material and a ... of delivering therapeutic molecules into cells and monitoring it ...

... 80% accuracy in prediction of the most effective drug against ... test that examines the// genetic material of a patient’s tumour. ... North Carolina report that this genomic test is useful in ... a particular cancer but also a combination of drugs. ...

... chefs are two to four times bigger than the government's ... contributing to increasing weight of their diners, the chefs believe ... ,These were the findings that were revealed by a ... the Obesity Society. ,A meal at a restaurant ...

... and bad news for women faced with the decision about ... is that screening mammography does reduce breast cancer mortality. The ... less likely to die of breast cancer than women who ... that women in a screened population are 30 percent more ...

... provide a scientific basis for eventual treatment, neurology researchers ... of a protein that// helps keep brain activity in ... to be an underlying reason for seizures and memory ... brain injury (TBI). ,“A traumatic brain injury ...

Cached Medicine News:Health News:Flaws Reported in overview of US organ transplants 2 Health News:Now, Silica Nanobubbles for Targeted Drug Delivery 2 Health News:Genomic tests for better cancer treatment 2 Health News:Portion Sizes in Restaurants Larger than Before 2 Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 2 Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 3 Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 4 Health News:How Brain Injury Leads to Seizures, Memory Problems 2

Flaws Reported in overview of US organ transplants Now, Silica Nanobubbles for Targeted Drug Delivery Genomic tests for better cancer treatment Portion Sizes in Restaurants Larger than Before Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis How Brain Injury Leads to Seizures, Memory Problems

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Diethyldithiocarbamate 2,4-Dichlorophenoxyacetic Acid, Urine 2,4-Dichlorophenoxyacetic Acid, Serum or Plasma Dibucaine